Bevacizumab in heavily pre-treated ovarien cancer patients and the predictive value of serum VEGF

Maja Smerdel; Karina Dahl Steffensen; Marianne Waldstrøm; Ivan Brandslund; Anders Jakobsen

Bevacizumab in heavily pre-treated ovarien cancer patients and the predictive value of serum VEGF

Maja Smerdel, Karina Dahl Steffensen, Marianne Waldstrøm, Ivan Brandslund, Anders Jakobsen

The Faculty of Health Sciences

Research output: Contribution to conference without publisher/journal › Conference abstract for conference › Research › peer-review

Original language	English
Publication date	2009
Publication status	Published - 2009
Event	ECCO 15-ESMO34 (ECCO - the European Cancer Organisation - ESMO - the European Society for Medical Oncology) - Berlin, Germany Duration: 20. Sep 2009 → 24. Sep 2009

Conference

Conference	ECCO 15-ESMO34 (ECCO - the European Cancer Organisation - ESMO - the European Society for Medical Oncology)
Country/Territory	Germany
City	Berlin
Period	20/09/2009 → 24/09/2009

Bibliographical note

Citation: European Journal of Cancer Supplements, Volume 7, Issue 2, September 2009, Page 451

Oral presentation

Documents & Links

http://www.sciencedirect.com/science/article/pii/S1359634909715253

Cite this

Smerdel, M., Dahl Steffensen, K., Waldstrøm, M., Brandslund, I., & Jakobsen, A. (2009). Bevacizumab in heavily pre-treated ovarien cancer patients and the predictive value of serum VEGF. Abstract from ECCO 15-ESMO34 (ECCO - the European Cancer Organisation - ESMO - the European Society for Medical Oncology), Berlin, Germany. http://www.sciencedirect.com/science/article/pii/S1359634909715253

@conference{59b2a4c0aced11de9743000ea68e967b,

title = "Bevacizumab in heavily pre-treated ovarien cancer patients and the predictive value of serum VEGF",

author = "Maja Smerdel and {Dahl Steffensen}, Karina and Marianne Waldstr{\o}m and Ivan Brandslund and Anders Jakobsen",

note = "Citation: European Journal of Cancer Supplements, Volume 7, Issue 2, September 2009, Page 451 Oral presentation; null ; Conference date: 20-09-2009 Through 24-09-2009",

year = "2009",

language = "English",

}

Smerdel, M, Dahl Steffensen, K, Waldstrøm, M, Brandslund, I & Jakobsen, A 2009, 'Bevacizumab in heavily pre-treated ovarien cancer patients and the predictive value of serum VEGF', ECCO 15-ESMO34 (ECCO - the European Cancer Organisation - ESMO - the European Society for Medical Oncology), Berlin, Germany, 20/09/2009 - 24/09/2009. <http://www.sciencedirect.com/science/article/pii/S1359634909715253>

Bevacizumab in heavily pre-treated ovarien cancer patients and the predictive value of serum VEGF. / Smerdel, Maja; Dahl Steffensen, Karina; Waldstrøm, Marianne; Brandslund, Ivan ; Jakobsen, Anders.

2009. Abstract from ECCO 15-ESMO34 (ECCO - the European Cancer Organisation - ESMO - the European Society for Medical Oncology), Berlin, Germany.

Research output: Contribution to conference without publisher/journal › Conference abstract for conference › Research › peer-review

TY - ABST

T1 - Bevacizumab in heavily pre-treated ovarien cancer patients and the predictive value of serum VEGF

AU - Smerdel, Maja

AU - Dahl Steffensen, Karina

AU - Waldstrøm, Marianne

AU - Brandslund, Ivan

AU - Jakobsen, Anders

N1 - Citation: European Journal of Cancer Supplements, Volume 7, Issue 2, September 2009, Page 451 Oral presentation

PY - 2009

Y1 - 2009

M3 - Conference abstract for conference

Y2 - 20 September 2009 through 24 September 2009

ER -